PUBLISHER: The Business Research Company | PRODUCT CODE: 2111407
PUBLISHER: The Business Research Company | PRODUCT CODE: 2111407
Electronic quality management system (EQMS) for pharma and medtech refers to digital platforms designed to manage and automate quality-related processes across regulated life sciences environments. These systems enable structured handling of quality events, including deviations, corrective and preventive actions (CAPA), document control, audits, compliance tracking, and training management.
The primary components of electronic quality management system (EQMS) for pharma and medtech include software and services. Software refers to digital platforms that streamline quality processes, ensure regulatory compliance, and manage documentation across pharmaceutical, biotechnology, and medical device organizations. These solutions are deployed through on-premises and cloud-based models and are adopted by small and medium enterprises as well as large enterprises. The key applications include document management, change management, corrective and preventive action management, training management, audit management, supplier quality management, and others, while the end-users include pharmaceutical companies, biotechnology companies, medical device manufacturers, and others.
Tariffs are influencing the electronic quality management system (EQMS) for pharma and medtech market by increasing the cost of software infrastructure, cloud hosting environments, validation tools, and implementation services required for quality and compliance management. This is raising deployment and operational expenses for software and services segments, particularly among pharmaceutical companies, biotechnology companies, and medical device manufacturers. Cloud-based deployments and validation-related services are most affected, while North America, Europe, and Asia-Pacific are experiencing cost pressures due to reliance on global technology ecosystems and specialized compliance resources. However, tariffs are also encouraging regional software development, local validation expertise, and greater investment in domestic quality management technology capabilities, supporting long-term market resilience and regulatory compliance.
The electronic quality management system (EQMS) for pharma and medtech market size has grown rapidly in recent years. It will grow from $2.9 billion in 2025 to $3.27 billion in 2026 at a compound annual growth rate (CAGR) of 12.8%. The growth in the historic period can be attributed to growing regulatory scrutiny on quality and compliance processes, increasing adoption of digital quality documentation systems, rising need for standardized CAPA management practices, expanding focus on audit preparedness and inspection readiness, increasing demand for end-to-end quality process visibility.
The electronic quality management system (EQMS) for pharma and medtech market size is expected to see rapid growth in the next few years. It will grow to $5.22 billion in 2030 at a compound annual growth rate (CAGR) of 12.4%. The growth in the forecast period can be attributed to growing adoption of cloud-based EQMS platforms across life sciences organizations, increasing investment in predictive quality and risk management capabilities, rising demand for integrated supplier quality management solutions, expanding implementation of automated compliance monitoring frameworks, increasing focus on scalable quality management systems for global operations. Major trends in the forecast period include increasing adoption of centralized quality event management platforms, growing implementation of automated CAPA workflows for compliance management, rising demand for digital document control and version management systems, expanding use of audit management solutions to strengthen regulatory readiness, increasing focus on employee training and qualification tracking across regulated environments.
The rising regulatory inspections and audits are expected to drive the growth of the electronic quality management system (EQMS) for pharma and medtech market in the coming years. Regulatory inspections and audits refer to structured assessments conducted by health authorities to ensure that pharmaceutical and medical technology organizations adhere to established quality and safety standards. The increase in regulatory inspections and audits is driven by more stringent compliance requirements imposed by regulatory bodies to ensure product quality, patient safety, and data integrity. Electronic quality management systems (EQMS) for pharma and medtech support regulatory inspections and audits by centralizing quality documentation, automating compliance workflows, and enabling rapid access to accurate audit records. For instance, in March 2024, according to the twelfth annual survey of the International Forum of Independent Audit Regulators (IFIAR), a Japan-based organization, all five inspection areas showed an increase in the proportion of listed PIE audits inspected that identified at least one finding compared to the 2022 survey. Therefore, the growing regulatory inspections and audits are driving the expansion of the electronic quality management system (EQMS) for pharma and medtech market.
Major companies operating in the electronic quality management system (EQMS) for pharma and medtech market are focusing on developing innovative solutions such as artificial intelligence (AI)-powered quality management platforms to enhance regulatory compliance, automate documentation workflows, and improve operational efficiency in life sciences organizations. Artificial Intelligence (AI)-powered quality management platforms are digital systems that use machine learning and automation to manage quality assurance and compliance processes, helping pharmaceutical and medtech companies reduce manual errors, streamline documentation, improve regulatory compliance, and accelerate decision-making. For instance, in April 2023, Dot Compliance, an Israel-based provider of compliance and quality management software for life sciences, launched the industry's first AI-based ChatGPT-powered eQMS for life sciences. The platform integrates embedded generative and predictive artificial intelligence with proprietary algorithms to automate quality management tasks, optimize compliance workflows, and improve reporting accuracy. It enables quality assurance professionals to automate document creation, deviation management, and regulatory reporting while enhancing organizational compliance performance. The solution is designed as a ready-to-use cloud-based platform that supports pharmaceutical and medtech companies in accelerating product development timelines and adapting to evolving regulatory requirements.
In April 2024, Clarivate Plc, a UK-based healthcare and information technology company, acquired Global QMS Inc. for an undisclosed amount. With this acquisition, Clarivate Plc aimed to strengthen its Life Sciences & Healthcare segment by integrating cloud-based regulatory reporting and compliance management solutions, thereby expanding its capabilities in manufacturing, supply chain management, and workflow automation for pharmaceutical, medtech, and biotech companies. Global QMS Inc. is a US-based healthcare technology company that specializes in providing quality-management-related solutions and consulting for regulated industries including pharmaceutical and medical device manufacturing.
Major companies operating in the electronic quality management system (eqms) for pharma and medtech market are Oracle Corporation; Siemens AG; Honeywell International Inc.; IQVIA Holdings Inc.; Dassault Systemes SE; Veeva Systems Inc.; MetricStream Inc.; MasterControl Inc.; ETQ (RPS Inc.); Ideagen plc; PSC Software; Ennov Group; ComplianceQuest Inc.; AmpleLogic Private Limited; AssurX Inc.; Intellect Design Arena Limited; Greenlight Guru LLC; Qualio Technologies Limited; Dot Compliance Ltd.; Scilife NV; QT9 Software Inc.; Omnex Systems LLC; Orcanos Ltd.; ZenQMS LLC; Trackmedium Pty Ltd.; Qualtrax; Pilgrim Quality Solutions
North America was the largest region in the electronic quality management system (EQMS) for pharma and medtech market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the electronic quality management system (EQMS) for pharma and medtech market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
The countries covered in the electronic quality management system (EQMS) for pharma and medtech market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The electronic quality management system (EQMS) for pharma and medtech market consists of revenues earned by entities by providing services such as software licensing and subscription, cloud-based deployment, system integration with enterprise and manufacturing systems, workflow automation, validation and compliance support, consulting, implementation services, training, technical support, and software maintenance and upgrades. The market value includes the value of related goods and digital tools sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end users are included.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
The electronic quality management system (eqms) for pharma and medtech market research report is one of a series of new reports from The Business Research Company that provides electronic quality management system (eqms) for pharma and medtech market statistics, including electronic quality management system (eqms) for pharma and medtech industry global market size, regional shares, competitors with a electronic quality management system (eqms) for pharma and medtech market share, detailed electronic quality management system (eqms) for pharma and medtech market segments, market trends and opportunities, and any further data you may need to thrive in the electronic quality management system (eqms) for pharma and medtech industry. This electronic quality management system (eqms) for pharma and medtech market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
Electronic Quality Management System (EQMS) For Pharma And Medtech Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses electronic quality management system (eqms) for pharma and medtech market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Where is the largest and fastest growing market for electronic quality management system (eqms) for pharma and medtech ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The electronic quality management system (eqms) for pharma and medtech market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.